Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Intelligent Bio Solutions ( (INBS) ) has issued an announcement.
On January 28, 2025, Intelligent Bio Solutions announced a significant partnership with IVY Diagnostics to expand its Intelligent Fingerprinting Drug Testing Solution in Europe and the Middle East. This collaboration is strategic due to the projected growth of the drug screening market in these regions, with Europe expected to reach $3.6 billion by 2030. IVY Diagnostics, leveraging its extensive network and expertise, will help INBS capture new opportunities, particularly in drug rehabilitation and law enforcement, with ongoing trials in Italy. This partnership positions the company to effectively meet the rising demand for efficient drug screening solutions.
More about Intelligent Bio Solutions
Intelligent Bio Solutions Inc. is a medical technology company focused on delivering innovative, rapid, non-invasive testing solutions. Its primary product is the Intelligent Fingerprinting Drug Screening System, which uses fingerprint sweat analysis for drug detection. The company targets various industries, including safety-critical sectors and drug treatment organizations, offering a system that provides quick results and is hygienic and cost-effective.
YTD Price Performance: 0%
Average Trading Volume: 117,263
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.97M
Learn more about INBS stock on TipRanks’ Stock Analysis page.
